Cash, cash equivalents and short-term investments totaled $224.6M at June 30. “We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-1290 in individuals living with Type 2 diabetes or obesity toward the end of the year,” said Raymond Stevens, founder and CEO of Structure Therapeutics. “With the recent announcement of Dr. Ted Love joining our Board, key milestones ahead and our strong cash runway, we believe we are well-positioned to execute on building our oral incretin franchise and have begun activities to prepare for a global Phase 2b study of GSBR-1290 in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GPCR:
- Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
- Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
- Structure Therapeutics initiated with an Overweight at Piper Sandler
- B. Riley biotechnology analysts to hold an analyst/industry conference call